Wielkopolskie Centrum Pulmonologii I Torakochirurgii Im. Eugenii I Janusza Zeylandow — Clinical Trial Site

61 Registered trials

33 Currently recruiting

Organisation

Wielkopolskie Centrum Pulmonologii I Torakochirurgii Im. Eugenii I Janusza Zeylandow

Location

Poznan, Poland

Identifier

ORG-100046609

Address

Ul. Augustyna Szamarzewskiego 62, 60-569, Poland

Departments

#5703 Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii
n/a
Oddzial Onkologii Klinicznej
Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii
Oddzial Onkologii Klinicznej z Pododzialem Dziennej Chemioterapii
Oddzial Onkologii z Pododdzialem Dziennej Chemioterapii
Oddzial Torakochirurgii
Oddział Onkologii Klinicznej z Pododdziałem Dziennej Chemioterapii
Oddział Onkologii Klinicznej z Pododdziałem Dziennej Chemioterapii
Oddział Onkologii Klinicznej z Pododdziałem Dziennej Chemioterapii
Oddział Onkologii Klinicznej z Pododdziałem Dziennej Chemioterapii
Oddział Onkologii Klinicznej z Pododdziałem Dziennej Chemioterapii Wielkopolskiego Centrum
Odzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii
Odział Onkologii Klinicznej z Pododdziałem Dziennej Chemioterapii
Oncology
Oncology Department
Oncology Departmet
POL005: Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii

Clinical trials at this site (61)

Search interface

KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di… Recruiting

2023-509234-19-00 Participants With Newly Diagnosed Resectable Stages II- 4 2025-03-03
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting

2023-509883-89-00 Epidermal growth factor receptor (EGFR) mutation-positi 5 2025-01-09
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting

2023-507778-42-00 Non-Small Cell Lung Cancer II, III 4 2023-03-08
A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended

2024-515772-12-00 Lung neoplasm malignant (Stage IV Non-small cell lung c 4 2025-04-18
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended

2022-501452-29-00 Metastatic Non-small Cell Lung Cancer 9 2024-08-28
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Ended

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended

2023-503575-21-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 5 2024-01-23
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended

2023-509943-28-00 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR 5 2022-05-18
A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s… Ended

2023-503868-16-00 Small-Cell Lung Cancer (SCLC) 5 2022-02-14
A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended

2023-506518-33-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2021-11-10